Device Trial Radar · NCT06420245
Clinical Utility of an Amniotic Membrane Allograft for Diabetic Foot Ulcer Wound Management
Last checked: Nov 20, 2026Latest source record: Aug 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
240
Planned (sponsor's estimate)
Start
Dec 30, 2025
Primary completion
Nov 2026
Study completion Jul 2027
Sponsor
- Lead sponsor
- Legacy Medical ConsultantsNot on our public-company list
- Sponsor type
- Industry
- First posted
- May 17, 2024
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (investigator)
- Primary purpose
- Supportive care
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 50 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn if use of Orion™, a dual-layer amniotic membrane allograft, in addition to standard wound care treatment can improve patient outcomes for people over the age of 50 with diabetic foot ulcers. The study aims to determine the incidence of complete wound closure at the end of 12 weeks of treatment. Researchers will compare the outcomes between a group of people treated with standard wound care and another group treated with standard wound care in addition to the amniotic membrane allograft to see if the amniotic membrane allograft improves wound healing. During the study, participants will visit their doctor weekly over a 12 week period, which is standard for diabetic foot ulcer treatment procedures, and fill out a questionnaire measuring quality of life.
Conditions
- Diabetic Foot Ulcer
Interventions
Orion TM Amniotic Membrane AllograftDevice
The intervention is a sterile allograft made from dehydrated extracellular matrix, designed to promote wound healing by providing a reliable and protective wound covering. Amniotic membranes are hypothesized to promote healing in open wounds by serving as a scaffold to support native tissue ingrowth, encouraging angiogenesis, and limiting microbial spread.
Standard of Care (SOC)Procedure
Standard wound care entails surgical debridement as needed to remove all non-viable tissue, screening for infection and probing of the wound for bone, weekly application of a collagen alginate primary dressing, and off-loading using a removable diabetic offloading cam-walker or total contact cast.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Complete Wound ClosureTime frame: starting from randomization until last visit of the 12-week wound management period
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
DPMG
Palm Springs, California
Center for Clinical Research Inc.
San Francisco, California
ILD Research Center
Vista, California
5 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.